Share Prices & Company Research

Stockbroking

Arix Bioscience

Current Price 106.00p Bid 101.00p Ask 111.00p Change 6.53%
Last Updated: 20/09/2020 02:03. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

Arix Bioscience is a global healthcare and life science company that drives value in private and public companies through operational and strategic direction as well as patient capital

Financial Highlights Year Ended 31/12/2019

Revenue
£-58.64m
Operating Profit/Loss
£-67.84m
Dividend yield (%)
n/a
Total dividend for year
n/ap
Dividend cover
n/a
P/E Ratio
n/a

Key Personnel

Mr Graeme Smith
Chief Scientific Officer
Mr Naseem Amin
Executive Chairman
Mr Marcus Karia
Group Finance Director
Prof Trevor Jones
Independent Non-Executive Director
Mr Jonathan Peacock
Non-Executive Chairman
Mr Arthur Pappas
Non-Executive Director
Mr Giles Kerr
Non-Executive Director
Mr Mark Breuer
Non-Executive Director

Stock Details

EPIC
ARIX
ISIN
GB00BD045071
Shares in Issue
135.61m
Market cap
£143.75m
Sector

Analyst Views (2)

Strong Buy
 
100.00%
Buy
 
0%
Hold
 
0%
Sell
 
0%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect view held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
106.00p
Bid Price
101.00p
Ask Price
111.00p
Volume
140,104
Change Today
6.50p
% Change Today
6.53%
Open
99.50p
Previous Close
106.00p
Intraday High
106.00p
Intraday Low
97.77p
52 Week High
121.00p
52 Week Low
58.50p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

Income Statement

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Continuing Operations
Revenue
-58.64
51.17
Operating Profit/Loss
-67.84
40.80
Net Interest
0.77
0.71
Pre-Tax Profit
-75.57
42.76
Profit After Tax from continuing operations
-69.69
36.88
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
-69.68
36.88
Attributable to:
Equity Holders of Parent Company
-69.68
36.88
Minority Interests
n/a
n/a
Total Dividend Paid
n/ap
n/ap
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2019
31 Dec 2018
Basic
-53.80p
32.10p
Diluted
-53.80p
29.70p
Adjusted
-53.80p
32.10p
Dividend per Share
n/ap
n/ap

Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Non-Current Assets
Property, Plant & Equipment
0.41
0.31
Intangible Assets
0.69
1.77
Investment Properties
0.37
n/a
Investments
151.92
183.98
Other Financial Assets
n/a
n/a
Other Non-Current Assets
n/a
n/a
Current Assets
Inventories
n/a
n/a
Trade & Other Receivables
1.11
2.17
Cash at Bank & In Hand
54.64
91.22
Current Asset Investments
n/a
n/a
Other Current Assets
0.09
n/a
Other Assets
n/a
n/a
Total Assets
209.22
279.46

Liabilities

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Current Liabilities
Borrowings
0.69
n/a
Other Current Liabilities
6.15
9.28
Total Current Liabilities
6.84
9.28
Non-Current Liabilities
Borrowings
0.27
n/a
Provisions
n/a
n/a
Other Non-Current Liabilities
n/a
n/a
Total Non-Current Liabilities
0.27
n/a
Other Liabilities
n/a
n/a
Total Liabilities
7.11
9.28

Net Assets

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Net Assets
202.11
270.17

Capital & Reserves

Year End Date
31 Dec 2019
31 Dec 2018
 
£ (M)
£ (M)
Share Capital
188.59
188.59
Share Premium Account
n/a
n/a
Other Reserves
-2.19
-0.43
Retained Earnings
15.72
82.02
Shareholders Funds
202.11
270.17
Minority Interests/Other Equity
n/a
n/a
Total Equity
202.11
270.17

Dividend History

Dividend Metrics

Year End Date
31 Dec 2019
31 Dec 2018
Dividend growth
n/a%
n/a%
Dividend yield
n/a%
n/a%
Dividend cover
n/a
n/a
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.